Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning

Abstract

Background There is a limited amount of data on the safety profile of the COVID-19 vector vaccine Gam-COVID-Vac (Sputnik V). Previous infodemiology studies showed that social media discourse could be analyzed to assess the most concerning adverse events (AE) caused by drugs. Objective We aimed to investigate mild AEs of Sputnik V based on a participatory trial conducted on Telegram in the Russian language. We compared AEs extracted from Telegram with other limited databases on Sputnik V and other COVID-19 vaccines. We explored symptom co-occurrence patterns and determined how counts of administered doses, age, gender, and sequence of shots could confound the reporting of AEs. Methods We collected a unique dataset consisting of 11,515 self-reported Sputnik V vaccine AEs posted on the Telegram group, and we utilized natural language processing methods to extract AEs. Specifically, we performed multilabel classifications using the deep neural language model Bidirectional Encoder Representations from Transformers (BERT) “DeepPavlov,” which was pretrained on a Russian language corpus and applied to the Telegram messages. The resulting area under the curve score was 0.991. We chose symptom classes that represented the following AEs: fever, pain, chills, fatigue, nausea/vomiting, headache, insomnia, lymph node enlargement, erythema, pruritus, swelling, and diarrhea. Results Telegram users complained mostly about pain (5461/11,515, 47.43%), fever (5363/11,515, 46.57%), fatigue (3862/11,515, 33.54%), and headache (2855/11,515, 24.79%). Women reported more AEs than men (1.2-fold, P<.001). In addition, there were more AEs from the first dose than from the second dose (1.1-fold, P<.001), and the number of AEs decreased with age (β=.05 per year, P<.001). The results also showed that Sputnik V AEs were more similar to other vector vaccines (132 units) than with messenger RNA vaccines (241 units) according to the average Euclidean distance between the vectors of AE frequencies. Elderly Telegram users reported significantly more (5.6-fold on average) systemic AEs than their peers, according to the results of the phase 3 clinical trials published in The Lancet. However, the AEs reported in Telegram posts were consistent (Pearson correlation r=0.94, P=.02) with those reported in the Argentinian postmarketing AE registry. Conclusions After the Sputnik V vaccination, Russian Telegram users reported mostly pain, fever, and fatigue. The Sputnik V AE profile was comparable with other vector COVID-19 vaccines. Discussion on social media could provide meaningful information about the AE profile of novel vaccines.

Spectrum of Adverse Event Following COVID-19 Immunization in High Altitude, Nepal

“…Initially, countries like Peru, temporarily suspended the trials of Covid vaccine after finding neurological problems in one volunteer [15]. Furthermore, studies conducted in countries like Canada and Russia reported symptoms more among the female population than in male which is in contrast to the findings of our study [16,17].…”

Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries

“…Our models showed a higher risk for women and young people to experience AEs. A real-world study that reported AEFI of patients receiving BNT162b2 mRNA, mRNA-1273, or Ad26COV2 in one or two doses ( 35 ), an independent studies conducted with Gam-COVID also confirmed this result ( 33 , 36 ). The study of Ramasamy et al.…”

Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries

“…For most patients, at least one AEFI occurred with all types of vaccines during the first 24 hrs. after injection, and most of them qualified the symptoms as "very mild" or "mild" both after the first and second dose, except for mRNA-1273 for which nearly half of the volunteers reported moderate symptoms after the second dose as reported previously (18,20,(22)(23)(24)(25)(26)(27).…”

“…Our models showed a higher risk for women and young people to experience AEs. A real-world study that reported AEFI of patients receiving BNT162b2 mRNA, mRNA-1273, or Ad26COV2 in one or two doses (28) , an independent studies conducted with Gam-COVID also confirmed this results (26,29). The study of Ramasamy et al on ChAdOx1 showed more adverse events in the group of 18-55 years old (22).…”